An Act to bring down the cost of prescription drugs

This bill directs the Massachusetts Health Policy Commission to study the feasibility of creating a state-run program to manufacture generic or biosimilar prescription drugs. The study will analyze how such a program could increase competition, lower prices, and address drug shortages while examining current cost drivers and the competitive landscape of drug manufacturing. Commission members must submit a report with findings and recommendations, including a cost-benefit analysis and a potential implementation plan, to state officials within one year of the bill's passage.